Theratechnologies (THTX) Set to Announce Quarterly Earnings on Tuesday

Theratechnologies (NASDAQ:THTX – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, September 26th.

Theratechnologies (NASDAQ:THTX – Get Free Report) last posted its earnings results on Wednesday, July 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.16). The firm had revenue of $17.55 million for the quarter. On average, analysts expect Theratechnologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Get Theratechnologies alerts:

Theratechnologies Price Performance

NASDAQ:THTX opened at $2.14 on Friday. The firm has a market cap of $51.79 million, a price-to-earnings ratio of -1.41 and a beta of 1.25. The company has a 50 day moving average price of $1.87 and a 200-day moving average price of $2.99. Theratechnologies has a 1-year low of $0.90 and a 1-year high of $11.06.

Institutional Investors Weigh In On Theratechnologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. increased its holdings in Theratechnologies by 9.9% in the 4th quarter. Soleus Capital Management L.P. now owns 8,799,125 shares of the company’s stock worth $7,768,000 after acquiring an additional 791,411 shares in the last quarter. Morgan Stanley increased its holdings in Theratechnologies by 3.2% in the 4th quarter. Morgan Stanley now owns 7,877,403 shares of the company’s stock worth $6,954,000 after acquiring an additional 244,096 shares in the last quarter. Worth Venture Partners LLC increased its holdings in Theratechnologies by 11.8% in the 1st quarter. Worth Venture Partners LLC now owns 755,863 shares of the company’s stock worth $1,870,000 after acquiring an additional 79,900 shares in the last quarter. Osaic Holdings Inc. increased its holdings in Theratechnologies by 2.3% in the 2nd quarter. Osaic Holdings Inc. now owns 444,155 shares of the company’s stock worth $374,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its stake in Theratechnologies by 13.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 434,155 shares of the company’s stock worth $383,000 after purchasing an additional 49,950 shares during the last quarter.

Analysts Set New Price Targets

Separately, National Bank Financial lifted their target price on shares of Theratechnologies from C$1.75 to C$7.00 in a report on Tuesday, August 1st.

View Our Latest Report on Theratechnologies

Theratechnologies Company Profile

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients.

Read More

• Five stocks we like better than Theratechnologies
• Mega Cap Stocks: What They Are and How to Invest
• 3 Reasons This Sleeping Giant Is About To Wake Up
• What Are the FAANG Stocks and Are They Good Investments?
• MarketBeat Week in Review – 9/18 – 9/22
• Investing in Blue-Chip Stocks
• 52-week Low Names To Tip The Upside Scale In Your Favor

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.